Vaxcyte CFO Insider Filing Shows $2.51B Cash and $604.9M Half-Year Loss
Guggenhime returned 2,705 shares to Vaxcyte to settle taxes on vested restricted stock. The firm reported $2.51 billion in cash and investments at end of June, while operating expenses rose to $302.8 million in the second quarter and the six-month net loss reached $604.9 million as spending increased to hit clinical and manufacturing milestones.